Japanese Journal of Cancer and Chemotherapy最新文献_第5页

[Ⅱ. Precision Medicine in Cholangiocarcinoma]. [胆管癌中的精准医学]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01

Kei Nakagawa, Hideaki Sato, Masahiro Iseki, Shuichi Aoki, Akiko Kusaka, Daisuke Douchi, Takayuki Miura, Masaharu Ishida, Masamichi Mizuma, Michiaki Unno

引用次数: 0

[More Personalized Treatment using Diversified Molecular Targeted Therapy Strategies for EGFR Mutation-Positive Non-Small-Cell Lung Cancer-Sequential Treatment Comprising First- and Second-Line Therapy with EGFR-TKIs and Treatment Options in Combination with Anti-Angiogenic Agents]. [针对表皮生长因子受体突变阳性的非小细胞肺癌，采用多样化分子靶向治疗策略进行更个性化的治疗--包括表皮生长因子受体-TKIs一线和二线治疗以及与抗血管生成药物联合治疗的序贯治疗方案]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01

Nobuhiko Seki, Hiroshige Yoshioka, Satoshi Wakabayashi, Sotaro Enatsu

{"title":"[More Personalized Treatment using Diversified Molecular Targeted Therapy Strategies for EGFR Mutation-Positive Non-Small-Cell Lung Cancer-Sequential Treatment Comprising First- and Second-Line Therapy with EGFR-TKIs and Treatment Options in Combination with Anti-Angiogenic Agents].","authors":"Nobuhiko Seki, Hiroshige Yoshioka, Satoshi Wakabayashi, Sotaro Enatsu","doi":"","DOIUrl":"","url":null,"abstract":"For epidermal growth factor receptor(EGFR)gene mutation-positive advanced non-small-cell lung cancer, molecular targeted therapy with EGFR tyrosine kinase inhibitors(EGFR-TKIs)is the mainstay of treatment. In Japan, 5 EGFR-TKIs[gefitinib and erlotinib(first-generation), afatinib and dacomitinib(second-generation), and osimertinib(third-generation)]have been approved, and only ramucirumab, an anti-angiogenic agent, has been approved for use in combination with the first-generation EGFR-TKIs. Since only osimertinib is approved for use in second-line therapy in the patients with confirmed T790M mutation after EGFR-TKI treatment, any other EGFR-TKI than osimertinib has to be selected as the first-line therapy of sequential treatment using EGFR-TKIs both as first-line and second-line therapy. Treatment options vary widely, and it is therefore important to select an optimal treatment based on clinical information such as a subtype of the EGFR gene mutation, as well as the patient's preference to potentially use molecular targeted therapy for second-line therapy. This article outlines clinical study data on the use of EGFR-TKIs as first- and second-line therapies and the use in combination with anti-angiogenic agents. It also describes our clinical experience with a successful shift from first-line therapy with an EGFR-TKI to second-line therapy with EGFR-TKI in sequential treatment.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1003-1011"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Future Prospects of the Project to Develop Remote Robotic Surgery via a Commercial 5G Network Using the hinotori TM Surgical Robot System]. [使用 hinotori TM 手术机器人系统，通过商用 5G 网络开发远程机器人手术项目的未来前景]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01

Raizo Yamaguchi

引用次数: 0

[Long-Term Response to CDK4/6 Inhibitor for Multiple Metastases of Breast Cancer]. [CDK4/6抑制剂治疗乳腺癌多处转移的长期疗效]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01

Kenichi Sakurai, Shuhei Suzuki, Keita Adachi, Tomohiro Hirano, Hitomi Kubota, Ayaka Sakamoto, Akiko Osakaya, Shigeru Fujisaki, Toshiko Ono, Taiki Tsuji

{"title":"[Long-Term Response to CDK4/6 Inhibitor for Multiple Metastases of Breast Cancer].","authors":"Kenichi Sakurai, Shuhei Suzuki, Keita Adachi, Tomohiro Hirano, Hitomi Kubota, Ayaka Sakamoto, Akiko Osakaya, Shigeru Fujisaki, Toshiko Ono, Taiki Tsuji","doi":"","DOIUrl":"","url":null,"abstract":"The patient was a 60-year-old woman. She was diagnosed with hypertension, symptomatic epilepsy, renal failure, and cerebral infarction. During follow-up, she was found to have a mass in her left breast and was referred to our department. An irregular mass measuring 5 cm in diameter was palpated in the C region of the left breast. Multiple enlarged lymph nodes, thought to be metastases, were also palpated in the ipsilateral axillary lymph nodes. A needle biopsy revealed invasive ductal carcinoma, ER positive, PgR positive, HER2 negative, Ki-67 12%. A systemic examination revealed bone metastasis. Surgery was not possible due to comorbidities, so fulvestrant(500 mg/month)+denosumab(120 mg/month)was started. Furthermore, as the tumor markers were elevated, abemaciclib(300 mg/day)was added, which resulted in a decrease in the tumor markers. After 1 month of administration, grade 3 neutropenia was observed, so the dosage was reduced to 200 mg/day. During the course of treatment, the tumor markers rose again, so the dose was increased to 250 mg/day, which resulted in a decrease in the tumor markers and good tolerability. At present, 36 months after the start of treatment, long SD has continued, no adverse events of grade 3 or higher have been observed, and the drug has been well tolerated.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1071-1073"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Real World Impact of Immunotherapy in Patients with Unresectable Gastric Cancer]. [免疫疗法对无法切除的胃癌患者的实际影响]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01

Takahiro Ryuzaki, Takako Sentsui, Seiji Kobayashi, Yukimasa Miyazawa, Soichiro Tsukamoto, Hirokazu Murayama, Hisami Yamakawa, Ryohei Kanamaru, Yoshio Koide, Yoshiji Watanabe, Tsutomu Yarita, Hisahiro Matsubara

{"title":"[Real World Impact of Immunotherapy in Patients with Unresectable Gastric Cancer].","authors":"Takahiro Ryuzaki, Takako Sentsui, Seiji Kobayashi, Yukimasa Miyazawa, Soichiro Tsukamoto, Hirokazu Murayama, Hisami Yamakawa, Ryohei Kanamaru, Yoshio Koide, Yoshiji Watanabe, Tsutomu Yarita, Hisahiro Matsubara","doi":"","DOIUrl":"","url":null,"abstract":"[Objective]To clarify the effect of immunotherapy on unresectable gastric cancer. [Subjects and methods]The study included all 67 patients with gastric cancer cStage ⅣB treated with systemic chemotherapy at Yarita Hospital between January 2016 and December 2022. The following 2 groups were compared: early patients treated between 2016 and 2017 and late patients treated between 2018 and 2022. [Results]Nivolumab was used in 20 patients(30%), and there were no cases of discontinuation due to irAE. The median overall survival was 11 months(0-91 months), with a duration of 13 months in the early group and 8.5 months in the late group(p=0.02). The transition rate to the third-line or later treatments increased from 6 of 27 patients(22%)in the early group to 13 of 40 patients(33%)in the late group(p=0.02). [Discussion]For patients evaluated in this study, the first and second treatment courses were introduced in the short-term, with the hope of subsequent treatment, even for patients with large ascites, poor PS, or complications. In recent years, drugs for the fourth-line and later treatments have been introduced, and we have observed patients for whom the latter treatment was effective.[Conclusion]The transition rate to the third-line or later treatments of patients with unresectable gastric cancer is increasing.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1056-1058"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Primary Hepatic Lymphoma Diagnosed by Laparoscopic Hepatectomy Affiliation]. [腹腔镜肝切除术确诊原发性肝淋巴瘤一例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01

Naoto Nishida, Kazuya Maeda, Takashi Sugio, Haruka Kubo, Kenji Dohden, Yasuharu Kaizaki, Yosuke Kato

{"title":"[A Case of Primary Hepatic Lymphoma Diagnosed by Laparoscopic Hepatectomy Affiliation].","authors":"Naoto Nishida, Kazuya Maeda, Takashi Sugio, Haruka Kubo, Kenji Dohden, Yasuharu Kaizaki, Yosuke Kato","doi":"","DOIUrl":"","url":null,"abstract":"An 88-year-old man was referred to our hospital for further examination of an asymptomatic liver tumor. MRI showed low-intensity regions on T1-weighted images, high-intensity regions on T2-weighted images, high-intensity regions on diffusion-weighted images, and low-intensity regions in the arterial, portal, and hepatocyte phases of Gd-EOB-DTPA. PET scan of the tumor was positive, while endoscopy exhibited no malignant findings. The CT and MRI findings showed that the tumor could be a metastatic liver tumor, cholangiocellular carcinoma, or hepatic inflammatory pseudotumor. Considering the possibility of a malignant tumor, laparoscopic partial hepatectomy was performed as a diagnostic treatment. The patient was discharged on the 8th postoperative day. The histopathological diagnosis was diffuse large B-cell lymphoma. Since the lesion was localized to the liver, a diagnosis of malignant lymphoma originating from the liver was made. Six courses of R-THP-COP therapy were administered. No indication of recurrence was noted 18 months after surgery. Although primary hepatic lymphoma is difficult to diagnose, laparoscopic hepatectomy allows for an accurate diagnosis and early postoperative recovery, enabling rapid administration of chemotherapy.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1025-1027"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Ⅲ. Precision Medicine for Gallbladder Cancer]. [精准医学治疗胆囊癌]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01

Masataka Ando, Yasuyuki Fukami, Tsuyoshi Sano

引用次数: 0

[Encapsulated Papillary Carcinoma and Mucinous Carcinoma in a Case of Locally Advanced Bilateral Breast Cancer]. [一例局部晚期双侧乳腺癌中的包裹性乳头状癌和粘液腺癌]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01

Shuhei Suzuki, Kenichi Sakurai, Tomohiro Hirano, Keita Adachi, Hitomi Kubota, Hisao Yagishita, Takuo Henmi, Hitoshi Tsuda

引用次数: 0

[Hyperthermia Enhances Antitumor Effects of Immune Checkpoint Inhibitors and Immune Cell Therapy]. [热疗增强免疫检查点抑制剂和免疫细胞疗法的抗肿瘤效果］

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01

Tsutomu Takeda, Daisaku Yamada, Sachika Amano, Takashi Takeda, Yui Kubota, Akika Kubota, Yuhki Yokoyama, Hiroko Takeda, Hirofumi Yamamoto

{"title":"[Hyperthermia Enhances Antitumor Effects of Immune Checkpoint Inhibitors and Immune Cell Therapy].","authors":"Tsutomu Takeda, Daisaku Yamada, Sachika Amano, Takashi Takeda, Yui Kubota, Akika Kubota, Yuhki Yokoyama, Hiroko Takeda, Hirofumi Yamamoto","doi":"","DOIUrl":"","url":null,"abstract":"Hyperthermia is known to enhance the effects of radiotherapy and chemotherapy. We have previously shown that hyperthermia also enhances the effects of molecular targeted therapy, immune cell therapy, and immune checkpoint inhibitors (ICI). Here, we present the recent clinical data and research results that suggest the mechanism of enhancement. Clinical data: We treated 3,419 advanced or recurrent cancer patients between June 2005 to December 2023. The effective rate (CR+PR+long term SD)was 19.7%. The effective rate of 2,329 patients treated with dendritic cells was 25.4%. The effective rate of 140 patients treated with combined dendritic cell therapy and ICI was high at 56.4%, and increased from 40.0 to 57.7% by the addition of hyperthermia. Clinical tissue: Hyperthermia promoted immune cell infiltration and enhanced MHC-class Ⅰ and PD-L1. Animal experiments: We have previously reported that hyperthermia promotes immune cell infiltration and increases MHC-class Ⅰ and PD-L1. We showed that hyperthermia increased p-STAT1 and IRF1 followed by PD-L1 expression. This study suggested that hyperthermia increased ICI through immune cell infiltration and expression of p-STAT1 and IRF1 pathways.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1053-1055"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Giant Intra-Abdominal Desmoid Tumor-A Case Report]. [腹腔内巨大蝶形瘤一例--病例报告]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01

Kotaro Miyamoto, Daiki Yamaguchi, Takeshi Tada, Koichi Nakayama, Kojiro Urazumi

引用次数: 0